JP2015504081A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504081A5
JP2015504081A5 JP2014552655A JP2014552655A JP2015504081A5 JP 2015504081 A5 JP2015504081 A5 JP 2015504081A5 JP 2014552655 A JP2014552655 A JP 2014552655A JP 2014552655 A JP2014552655 A JP 2014552655A JP 2015504081 A5 JP2015504081 A5 JP 2015504081A5
Authority
JP
Japan
Prior art keywords
alkyl
independently
different
phenyl
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014552655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504081A (ja
JP6128133B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/051097 external-priority patent/WO2013110585A1/en
Publication of JP2015504081A publication Critical patent/JP2015504081A/ja
Publication of JP2015504081A5 publication Critical patent/JP2015504081A5/ja
Application granted granted Critical
Publication of JP6128133B2 publication Critical patent/JP6128133B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014552655A 2012-01-23 2013-01-22 Igf−1r/ir阻害剤としての5,8−ジヒドロ−6h−ピラゾロ[3,4−h]キナゾリン Active JP6128133B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152193.4 2012-01-23
EP12152193 2012-01-23
PCT/EP2013/051097 WO2013110585A1 (en) 2012-01-23 2013-01-22 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors

Publications (3)

Publication Number Publication Date
JP2015504081A JP2015504081A (ja) 2015-02-05
JP2015504081A5 true JP2015504081A5 (US20070167479A1-20070719-C00034.png) 2016-03-10
JP6128133B2 JP6128133B2 (ja) 2017-05-17

Family

ID=47605520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014552655A Active JP6128133B2 (ja) 2012-01-23 2013-01-22 Igf−1r/ir阻害剤としての5,8−ジヒドロ−6h−ピラゾロ[3,4−h]キナゾリン

Country Status (7)

Country Link
US (1) US9150578B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP2807166B1 (US20070167479A1-20070719-C00034.png)
JP (1) JP6128133B2 (US20070167479A1-20070719-C00034.png)
AR (1) AR089776A1 (US20070167479A1-20070719-C00034.png)
TW (1) TW201343648A (US20070167479A1-20070719-C00034.png)
UY (1) UY34586A (US20070167479A1-20070719-C00034.png)
WO (1) WO2013110585A1 (US20070167479A1-20070719-C00034.png)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3189051A1 (en) * 2014-09-02 2017-07-12 Pierre Fabre Medicament Isoquinolinone derivatives useful in the treatment of cancer
WO2016180843A1 (en) * 2015-05-13 2016-11-17 Boehringer Ingelheim International Gmbh New 5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h]quinazolin-2- yl)-(1 h-pyrazol-3-yl)-amines and derivatives as igf-1 r/ir inhibitors
CN111094291B (zh) * 2017-08-11 2022-06-21 晟科药业(江苏)有限公司 1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023150663A1 (en) * 2022-02-04 2023-08-10 Retune Pharma Inc. Certain chemical entities, compositions, and methods
WO2024153226A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种吡唑并环类化合物、药物组合物及其用途
WO2024153237A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途
CN116473077A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种n,n配位的镓配合物抗菌剂的合成和应用
CN116458513A (zh) * 2023-05-08 2023-07-21 广东方中高新材料有限公司 一种含镓配合物的咪鲜胺增效水乳制剂及其制备方法
CN116473073A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE432929T1 (de) 2001-06-15 2009-06-15 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
CA2507406A1 (en) 2002-11-05 2004-05-21 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
CN1826343A (zh) * 2003-05-22 2006-08-30 法玛西雅意大利公司 吡唑并-喹唑啉衍生物、它们的制备方法和它们作为激酶抑制剂的用途
US20050075358A1 (en) 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CN101437822B (zh) * 2006-05-11 2012-11-28 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
US8735386B2 (en) 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines

Similar Documents

Publication Publication Date Title
JP2015504081A5 (US20070167479A1-20070719-C00034.png)
JP2017527532A5 (US20070167479A1-20070719-C00034.png)
JP2015078230A5 (US20070167479A1-20070719-C00034.png)
JP2016530259A5 (US20070167479A1-20070719-C00034.png)
WO2014209841A3 (en) Compounds for treating spinal muscular atrophy
JP2017510610A5 (US20070167479A1-20070719-C00034.png)
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
JP2014504622A5 (US20070167479A1-20070719-C00034.png)
JP2015516427A5 (US20070167479A1-20070719-C00034.png)
JP2014221779A5 (US20070167479A1-20070719-C00034.png)
JP2017524025A5 (US20070167479A1-20070719-C00034.png)
JP2015537020A5 (US20070167479A1-20070719-C00034.png)
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
JP2013032389A5 (US20070167479A1-20070719-C00034.png)
JP2014511892A5 (US20070167479A1-20070719-C00034.png)
JP2013523614A5 (US20070167479A1-20070719-C00034.png)
JP2016505637A5 (US20070167479A1-20070719-C00034.png)
JP2014500296A5 (US20070167479A1-20070719-C00034.png)
JP2014129360A5 (US20070167479A1-20070719-C00034.png)
JP2015527333A5 (US20070167479A1-20070719-C00034.png)
JP2014511891A5 (US20070167479A1-20070719-C00034.png)
WO2014147021A3 (en) 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
JP2016531871A5 (US20070167479A1-20070719-C00034.png)
WO2015021396A3 (en) Tricyclic benzoxaborole compounds and uses thereof
JP2017529357A5 (US20070167479A1-20070719-C00034.png)